Designing a biomedical cutter for heart valve leaflets

Vesalius Cardiovascular是一家生物医学设备企业，设计和开发用于二尖瓣返流的外科植入物和 ** 附件。**对于无法进行二尖瓣修复的二尖瓣返流患者，必须进行二尖瓣置换术 **。目前的金标准治疗是二尖瓣置换术，一种心内直视手术。但是由于心脏手术的风险，许多患者 ** 无法安全治疗，因此行业正在努力进行经皮二尖瓣置换术，这意味着瓣膜通过导管而不是开放手术进行置换。这种技术被称为 ** 经导管二尖瓣置换术（TMVR）。**植入经导管二尖瓣的尝试都受到与称为左心室流出道阻塞（LVOTO）的技术相关的严重和常见并发症的影响，这是一种致命的并发症。Vesalius方法是复制手术所做的，以避免这个问题，但仍然存在。在手术中，** 通过将前叶与主动脉流出道瓣膜旁的附件分开来避免该问题。** Vesalius溶液是一种经皮工具，用于在二尖瓣前叶中创建精确切口，然后可通过该工具沿用于创建切口的同一导丝快速植入经导管瓣膜。扩张的置换瓣膜使前叶远离主动脉流出道瓣膜，避免了LVOTO。

Vesalius Cardiovascular is a biomedical device venture designing and developing surgical implants and**accessories for mitral valve regurgitation.**For patients with mitral regurgitation for whom mitral valve repair is not possible, mitral valve replacement**becomes necessary. The current gold standard therapy is surgical mitral valve replacement, an open-heart**operation. But because of the risk of heart surgery, many patients**cannot be safely treated, and so industry is working toward percutaneous mitral valve replacement, which**means the valve is replaced through a catheter rather than with open surgery. This technique is called**Transcatheter Mitral Valve Replacement (TMVR).**Attempts to implant a transcatheter mitral valve have all been subject to a serious and common complication**related to the technique called Left Ventricular Outflow Tract Obstruction (LVOTO), a fatal complication.**Vesalius approach is to replicate what is done surgically to avoid this problem, but percutaneously. At surgery,**the problem is avoided by dividing the anterior leaflet from its attachment beside the aortic outflow valve.**Vesalius solution is a percutaneous tool for the creation of a precise cut in the anterior leaflet of the mitral**valve, through which a transcatheter valve may then be expeditiously implanted over**the same wire that has been used to create the cut. The expanded replacement valve moves**the anterior leaflet away from the aortic outflow valve, and LVOTO is avoided.